Garg Aarti, Pattamadilok Sirima, Bahl Sunil
World Health Organization Regional Office for South-East Asia, New Delhi, India.
WHO South East Asia J Public Health. 2018 Sep;7(2):122-128. doi: 10.4103/2224-3151.239424.
The last decade has witnessed an exponential expansion of environmental surveillance (ES) of poliovirus in sewage samples in the World Health Organization (WHO) South-East Asia Region. This has grown from only three sites in Mumbai, India in 2001 to 56 sites in 2017 in Bangladesh, India, Indonesia, Myanmar, Nepal and Thailand. ES is critical to the region in providing evidence of silent transmission of vaccine-derived poliovirus and Sabin-like poliovirus type 2 - especially since the global "switch" to cease use of oral polio vaccine type 2 - and for monitoring the effectiveness of containment activities. This targeted expansion of ES to supplement surveillance for acute flaccid paralysis (AFP) required quality assurance in ES procedures, improvements in the sensitivity of the laboratory-based surveillance system, and establishment of real-time data analysis for evidence-based programmes. ES in the region has provided documentary evidence for the absence of indigenous wild poliovirus in circulation and no importations via international travellers. Post-switch, while no vaccine-derived poliovirus was detected from AFP cases, ES identified five ambiguous vaccine-derived polioviruses in 2016 and early 2017, with no evidence of circulation. Future challenges include monitoring for vaccine-derived poliovirus strains shed for a prolonged time by immunodeficient individuals, and expanding ES to areas lacking sewage networks. To maintain the polio-free status of the WHO South-East Asia Region and achieve a world free of poliomyelitis, critical evaluation of immunization coverage, continued performance of surveillance for acute flaccid paralysis, and enhanced analysis of sewage samples to detect any breach in containment are essential.
在过去十年中,世界卫生组织(WHO)东南亚区域对污水样本中的脊髓灰质炎病毒进行的环境监测(ES)呈指数级扩展。这一监测工作从2001年印度孟买的仅三个监测点发展到2017年在孟加拉国、印度、印度尼西亚、缅甸、尼泊尔和泰国的56个监测点。环境监测对于该区域至关重要,它能提供疫苗衍生脊髓灰质炎病毒和2型萨宾样脊髓灰质炎病毒隐性传播的证据——尤其是自全球“转换”停止使用2型口服脊髓灰质炎疫苗以来——并用于监测控制活动的有效性。这种有针对性地扩展环境监测以补充急性弛缓性麻痹(AFP)监测,需要保证环境监测程序的质量,提高基于实验室的监测系统的灵敏度,并建立用于循证项目的实时数据分析。该区域的环境监测提供了文献证据,证明没有本土野生脊髓灰质炎病毒在传播,也没有通过国际旅行者传入。转换之后,虽然在急性弛缓性麻痹病例中未检测到疫苗衍生脊髓灰质炎病毒,但环境监测在2016年和2017年初发现了5株不明疫苗衍生脊髓灰质炎病毒,且没有传播迹象。未来的挑战包括监测免疫功能低下个体长时间排出的疫苗衍生脊髓灰质炎病毒株,以及将环境监测扩展到缺乏污水管网的地区。为保持WHO东南亚区域无脊髓灰质炎状态并实现全球无脊髓灰质炎,对免疫覆盖率进行严格评估、持续开展急性弛缓性麻痹监测以及加强对污水样本的分析以检测任何控制漏洞至关重要。